Nov 14 — China’s National Healthcare Security Administration said JW
Therapeutics’ CAR-T drug Ruijiaolunsai has been added to the National
Reimbursement Drug List. The therapy’s list price was 1.29 mln yuan per dose
prior to inclusion; inclusion has cut the price to below 300,000 yuan per dose,
according to Ma Jun, director of the Harbin Institute of Hematology and
Oncology, who took part in the drug’s review and clinical-consensus drafting.
